Connect Biopharma

Q2 FY2026 EarningsQ2 FY26 results exceeded expectations across major financial metrics, with revenue of $2.8M significantly beating the $0.6M consensus ($4.4M in CNY) due to regulatory milestones from Simcere. GAAP EPS of -$0.27 outperformed the -$0.32 consensus, despite an 85% YoY surge in R&D spending to $16.3M to support Phase 2 Seabreeze STAT trials. Management confirmed a cash runway extending at least one year and expects pivotal topline data for asthma and COPD treatments in September 2026.